10/1/2004

Mistletoe Complementary Treatment in Patients with Primary Non-metastatic Breast Cancer

Paul R. Bock et al.

By: Paul R. Bock et al.

Published By: Arzneim.-Forsch./Drug Research

The results of the present study confirmed the safety of the complementary therapy for patients with primary, non-metastatic mammary carcinoma with Iscador^® and showed considerably fewer ADRs attributed to concurrent conventional therapy, as well as reduced disease and treatment-associated symptoms, and suggested a prolonged overall survival in the Iscador^® group as compared with controls.